| Background and Objection:China is a medium endemic area of hepatitis B virus infection,with a hepatitis B surface antigen positive rate of about 7.18%in the normal population.A higher positive rate of about 13.5%has been reported in the normal population of Guangdong Province,where hepatitis B surface antigen positive rate ranks second in China.Patients with malignant hematologic disease are more likely to be infected by hepatitis B virus because of impaired immunologic function,multiple blood transfusion.The positive rate of hepatitis B surface antigen has been reported to be about 6.6%-10%in patients undergoing allogeneic hematopoietic stem cell transplantation in China,which was significantly higher than that in Europe and America.Hepatitis B virus(HBV)infection is one of the important reasons of liver injury and hepatic failure following hematopoietic stem cell transplantation.Patient with hepatitis B virus infection characterized by hepatitis B surface antigen are most likely undergoing hepatitis B virus reactivation after hematopoietic stem cell transplantation,with an incidence rate of about 21%-53%.Reactivation of hepatitis B virus may cause different degrees of hepatitis and the mortality rate of severe hepatitis has been reported to be more than 50%,so reactivation of hepatitis B virus severely affects the effectiveness and prognosis of hematopoietic stem cell transplantation patients.The patients with hematological diseases always have impaired immune function and have a high incidence of occult hepatitis B infection.Occult hepatitis B infection patients always show HBsAg negative,single or multiple antibody positive,even negative for all HBV serological markers,with low but persistent replication of the hepatitis B virus in liver cells and peripheral blood mononuclear cells of the patients.The incidence of HBV reactivation after chemotherapy and transplantation in patients with occult hepatitis B infection has been reported to be 21-67%.There still lack uniform standards about prevention of post-transplant HBV reactivation and hepatitis B virus infection in patients with occult hepatitis B infection.There is a considerable proportion of HBsAg positive donors with hepatitis B infection in allogeneic hematopoietic stem cell transplantation,which potentially infection HBsAg negative recepients through hepatitis B virus infected graft in the absence of anti hepatitis B virus therapy,with a reported infection rate of 22-55.5%.Even some patients with positive hepatitis B surface antibody before transplantation may lose the hepatitis B surface antibody after transplantation.These are all urgent problems remained to be solved in hematopoietic stem cell transplantation.Anti hepatitis B virus treatment has been recommended by several chronic hepatitis B clinical practice guidelines for patients with HBV infection undergoing hematopoietic stem cell transplantation to prevent hepatitis B virus reactivation,so as to reduce the incidence of post-transplant hepatitis B virus reactivation and related hepatitis.Lamivudine(LAM),the first nucleoside drugs applied to clinical,has showed significant ability to inhibit hepatitis B virus replication,improvement of liver function,reduced occurrence of liver cirrhosis and liver in the treatment of chronic hepatitis B.Lamivudine is also widely used in the prevention of reactivation of hepatitis B virus in chemotherapy and hematopoietic stem cell transplantation,which can reduce about 70%of the hepatitis B virus reactivation rate,but it also expose shortcomings such as drug resistance and recurrence after drug withdrawal in long-term clinical application.Entecavir(ETV),a new generation of nucleoside analogue,exhibit stronger antiviral ability and lower resistance rate than lamivudine as well as improve liver function of patients in the treatment of chronic hepatitis B.However there are rarely reports about the efficacy and safety of entecavir for the prevention of hepatitis B virus reactivation in the treatment of allogeneic hematopoietic stem cell transplantation,comparison studies of these two drugs are also rarely reported.However,many problems such as drug resistance,poor compliance,not elimination of hepatitis B virus infection,the recurrence rate after drug withdrawal have been shown in long-term clinical application of nucleoside analogues.Hepatitis B vaccine was used by some researchers to prevent post-transplantation hepatitis B infection for hematopoietic stem cell transplantation patients,but there are some shortcomings such as no response or low response,the limited preventive effect and so on.The use of hepatitis B surface antigen stimulated dendritic cells for therapy of patients with chronic hepatitis B has been reported to be effective in inducing HBeAg/HBeAb seroconversion and HBV DNA negative in some studies.There are also some clinical manifestation of adoptive immunity transfer of immunity to hepatitis B virus have been reported in the kidney,heart,pancreas,liver and other organ transplantation in recent years.But adoptive immunity transfer in both adoptive cellular immunotherapy and solid organ transplantation can’t lead to seroclearance of hepatitis B surface antigen,suggesting incapability of complete removal of the hepatitis B virus(HBV)infection.Allogeneic hematopoietic stem cell transplantation,a kind of thorough adoptive immunity transfer and reconstitution,is the most promising method to use the donors derived normal immune cells to eliminate the hepatitis B virus infection in the recipients.Shouval et al report that hepatitis B surface antibody negative mice seroconvert from HBsAb-to HBsAb+after bone marrow transplanted from the mice with positive antibody to hepatitis B surface antibody.Ilan et al retrospectively found 12 patients with negative HBV serum markers seroconvert from HBsAb-to HBsAb+after bone marrow transplanted from the donors with positive antibody to hepatitis B surface antibody and hepatitis B core antibody,with an average hepatitis B surface antibody titer of 155+33mIU/ml.In the following subsequent prospective study,the researchers found that 22 of 35 patients with negative HBV serum markers before transplantation seroconvert from HBsAb-to HBsAb+after transplanted from the donors with positive antibody to hepatitis B surface antibody.The above animal and clinical studies demonstrated a transfer of HBV specific immunity against hepatitis B from the donor to the recipients via hematopoietic stem cell transplantation resulting in obtain of normal HBV immunity of the recipients.But these studies be confined to small number of samples and less type combinations of different HBV serological of the donors and recipients,therefore could not fully reflect the the clinical characteristics of adoptive immunity transfer of immunity to hepatitis B in allogeneic hematopoietic stem cell transplantation.In our study,a retrospective review was performed on adult patients undergoing allogeneic hematopoietic stem cell transplantation.The changes of HBV serological markers,HBV DNA and liver biochemical indexes before and after transplantation,and their relationship with the serum markers of hepatitis B virus of donors was also analyzed.The study aimed to analysis the clinical features of adoptive immunity transfer of immunity to hepatitis B virus in allogeneic hematopoietic stem cell transplantation.In our study,we further studied the efficacy of lamivudine and entecavir for prevention of hepatitis B virus reactivation in patients undergoing allogeneic hematopoietic stem cell transplantation so as to analysis the synergistic effect of adoptive immunity transfer of immunity to hepatitis B virus and nucleoside drugs on the prevention and treatment of hepatitis B virus infection in patients undergoing hematopoietic stem cell transplantation.Methods and Patients:1)Clinical features of adoptive immunity transfer of immunity to hepatitis B virus in allogeneic hematopoietic stem cell transplantation:A retrospective review was performed on 351 patients undergoing allogeneic hematopoietic stem cell transplantation in muIticenters(Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou;Department of Hematology,Union Hospital affiliated to Fujian Medical University,Fuzhou;Department of Hematology,Fujian Provincial Hospital,Fuzhou)from January 2006 to March 2015.The patient enrolled were required to meet the following conditions,older than 14 years with complete follow-up data of hepatitis B serological markers,hepatitis B virus DNA and liver biochemical indexes before and after allogeneic hematopoietic stem cell transplantation.Those recipients with hepatitis A,hepatitis C,hepatitis,syphilis and human immunodeficiency virus infections as well as poor medicine taking compliance were excluded.The primary focus of this study was seroconversion of hepatitis B surface antibody(HBsAb),reactivation of hepatitis B virus,hepatitis B surface antigen(HBsAg)seroclearance and hepatitis B virus infection following transplantation.The main outcome measures were as follows:I)Hepatitis B virus serum markers:hepatitis B surface antigen(HBsAg),hepatitis B surface antibody(HBsAb),hepatitis B e antigen(HBeAg),hepatitis B e antibody(HBeAb),hepatitis B core antibody(HBcAb);2)Hepatitis B virus load;3)Liver biochemical indexes:alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),direct bilirubin(DBIL).The above indicators were measured before and after transplantation in all recipients,follow up according to clinical suggestion or symptoms.The study aimed to analysis the changes of HBV serological markers,HBV DNA and liver biochemical indexes of the patients before and after transplantation,and their relationship with the serum markers of hepatitis B virus of donors.so as to analysis the clinical features of adoptive immunity transfer of immunity to hepatitis B virus in allogeneic hematopoietic stem cell transplantation.2)The efficacy of lamivudine and entecavir for prevention of hepatitis B virus reactivation in patients undergoing allogeneic hematopoietic stem cell transplantation:A retrospective review was performed on 234 patients undergoing allogeneic hematopoietic stem cell transplantation in multicenters(Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou;Department of Hematology,Union Hospital affiliated to Fujian Medical University,Fuzhou;Department of Hematology,Fujian Provincial Hospital,Fuzhou)from January 2006 to March 2015.The patient enrolled were required to meet the following conditions,older than 14 years with complete follow-up data of hepatitis B serological markers,hepatitis B virus DNA and liver biochemical indexes before and after allogeneic hematopoietic stem cell transplantation,hepatitis B surface antigen positive and received lamivudine or lamivudine as anti hepatitis B virus treatment before transplantation.Those recipients with hepatitis A,hepatitis C,hepatitis,syphilis and human immunodeficiency virus infections as well as prior use of other anti hepatitis B virus drugs such as adefovir dipivoxil,interferon,hepatitis B virus immune globulin therapy and poor medicine taking compliance patients were excluded.100 mg/d oral lamivudine or entecavir orally 0.5 mg/d was started at least one month before the transplant and the drug was discontinued for 6 months after the end of the transplantation and the immunosuppressive agents were stopped.Post transplant HBV virological response and clearance of hepatitis B surface antigen,hepatitis B virus reactivation and hepatitis B virus reactivation of hepatitis clinical features of lamivudine and entecavir treatment and the related risk factors was analyzed.All statistical analyses were performed using SPSS 16.0 software(SPSS,Chicago,IL,USA).The numeration data were analyzed by Chi-square test,The difference of measurement data was compared with the independent t-test or analysis of variance.Cumulative incidence curves were used to calculate the incidence of mainly observed events for both groups.Differences between cumulative incidence curves were tested using the log rank test.Univariate and multivariate Cox regression analyses were used to identify risk factors that predispose patients to HBV reactivation and related hepatitis infection.Variables for the multivariate model were selected using backward stepwise elimination using significance of P>0.05 as the criterion for removal from the model.A two-tailed value of P<0.05 was considered statistically significant.Results:1.Clinical featuresofadoptiveimmunity transfer of immunity to hepatitis B virusin allogeneic hematopoietic stemcell transplantation:(1)Clinical data and grouping:351 patients undergoing allogeneic hematopoietic stem cell transplantation who met the inclusion criteria were enrolled in the first part of our study.There were 209 males and 142 females;the median age was 28(14-61)years;the median follow-up time was 19(5-36)months.Primary diseases include 120 cases of acute lymphoblastic leukemia,169 cases of acute myeloid leukemia,12 cases of aplastic anemia,29 cases of chronic myeloid leukemia,13 cases of myelodysplastic syndrome,8 cases of non Hodgkin’s lymphoma.Before transplantation,286 patients were in complete remission(remission completely,CR),and 65 patients were in the non CR state.280 patients received donor transplantation,71 patients received unrelated donor transplantation.The methods of transplantation include peripheral blood stem cell transplantation in 273 cases,9 cases of bone marrow transplantation,69 cases of peripheral blood stem cell combined with bone marrow transplantation.The patients were divided into 6 groups according combination mode of donor and recipient with different hepatitis B serological markers before transplantation:Group 1(donor HBsAb-and recipient HBsAb-)16 patients,group 2(donor HBsAb-and recipient HBsAb+)31 patients,Group 3(donor HBsAb+and recipient HBsAb-)33 patients,group 4(donor HBsAb+and recipient HBsAb+)158 patients,group 5(donor HBsAb+and recipient HBsAg+)82 patients,group 6(donor HBsAb-and recipient HBsAg+)31 patients.(2)Effect of adoptive immunity transfer of immunity to hepatitis B virus on seroconvert from HBsAb-to HBsAb+in patients undergoing allogeneic hematopoietic stem cell transplantation:Of the 33 patients in group 3 who were HBsAb-and transplant from HBsAb+donor,20 patients(60.6%)seroconvert from HBsAb-to HBsAb+with a median time of 2(1.5-4)months after transplantation and the average serum HBsAb titer was 105.76±17.45 mlU/ml,the other 13 patients(39.4%)remained HBsAb negative after transplantation.Of the 16 patients in group 1 who were HBsAb-and transplant from HBsAb-donor,no patient seroconvert from HBsAb-to HBsAb+(P<0.001),indicating obtain of HBsAb of HBsAb-recipients from HBsAb+donors by adoptive immunity transfer of immunity to hepatitis B virus after transplantation.Of the 20 patients who seroconvert from HBsAb-to HBsAb+in the group 3,4 patients experience HBsAb loss with a median time of 9(6-12)months after transplantation after.Hepatitis B virus serum markers did not change in the rest of the patients after transplantation.Of the 33 patients who maintained HBsAb negative after transplantation,10 patients(30.3%)seroconvert to HBsAg+with a median time of 14(6-23)months after transplantation.However,of the 16 patients who maintained HBsAb positive post-transplantation,no patient seroconvert from to HBsAg positive(P<0.001)with a median follow up of 18(12-25)months,indicating adoptive immunity transfer of immunity to hepatitis B virus effectively help to prevent HBV infection in recipients after transplantation.By multivariate Cox analysis,donor HBsAb positive is the only major factors leading to seroconvert from HBsAb-to HBsAb+in recipient after transplantation(HR=12.11,95%CI=3.23-42.37,P<0.001).(3)Effect of adoptive immunity transfer of immunity to hepatitis B virus on HBsAb loss in patients undergoing allogeneic hematopoietic stem cell transplantation:Of the 31 patients in group 2 who were HBsAb+and transplant from HBsAb-donors,19 patients(61.3%)exhibited HBsAb loss with a median time of 12(8-16)months after transplantation,the other 12(38.7%)patients remained HBsAb positive with a median follow-up time of 19(14-30)months and the average serum titer of HBsAb was 50.95±10.51 mIU/ml.Of the 158 patients in group 4 who were HBsAb+and transplant from HBsAb+donors,29 patients(18.4%)exhibited HBsAb loss with a median time of 12(8-18)months after transplantation(P<0.001),129 patients(81.6%)remained positive for HBsAb with an average serum HBsAb titer of155.33±31.3mIU/ml after a median follow-up of 20(9-36)months after transplantation.It suggested that adoptive immunity transfer of immunity to hepatitis B virus from HBsAb+donor help to reduce the loss of HBsAb after transplantation in pre-transplant HBsAb+recipients.Of the 48 patients who lost HBsAb after transplantation,5 patients(10.4%)seroconvert to HBsAg+with a median time of 14(10-19)months after transplantation indicating hepatitis B virus infection or reactivation of hepatitis B virus.However,of the 141 patients who remained HBsAb positive after transplant,no patient seroconvert to HBsAg+(P<0.001)with a median follow up of 20(9-36)months,indicating that recipients who remained sustained HBsAb positive after transplantation have strong immunity against hepatitis B infection.By univariate Cox analysis,donor HBsAb negative(HR=0.02,95%CI＝0.01-0.68,P<0.001)and the pre-transplantation HBsAb titer of recipients(HR=0.04,95%CI=0.01-0.87,P<0.001)arefactors affecting HBsAb loss in recipient after transplantation.By multivariate Cox analysis,donor HBsAb negative(HR=0.07,95%CI=0.02-1.13,P<0.001)and the pre-transplantation HBsAb titer of recipients(HR=0.1 1,95%CI=0.04-1.25,P<0.001)are major factors affecting HBsAb loss in recipient after transplantation.(4)Effect of adoptive immunity transfer of immunity to hepatitis B virus on HBsAg seroclearance in patients undergoing allogeneic hematopoietic stem cell transplantation:16(19.5%)HBsAg+patients of group 5 exhibit HBsAg seroclearance with a median time of 2.5(1.5-3)months after transplantation,all the 16 patients experience mild hepatitis with an average ALT level of 115.04±17.12 IU/L,the patients also exhibit seroconvert from HBsAb-to HBsAb+with an average serum HBsAb titer of 114.39±14.35 mIU/ml.Further analysis of the data showed that HBV serological markers of the 16 donors whose recipients exhibited HBsAg seroclearance were all HBsAb+/HBcAb+.Of all the 23 recipients with donors exhibited hepatitis B serological mark of HBsAb+/HBcAb+,16(69.6%)recipientsexperienced HBsAg seroclearance.However,59 patients in group 5 who were HBsAg+and transplant from HBsAb+only donors,no patient exhibit HBsAg seroclearance(P<0.001),indicating adoptive immunity transfer of immunity to hepatitis B virus from HBsAb+/HBcAb+donors leading to HBsAg seroclearance in pre-transplant HBsAg+recipients.Of the 31 patients in group 6 who were HBsAg+and transplant from HBsAb-donors,no patient exhibit HBsAg seroclearance.With a median follow up time of 24(16-24)months after transplantation,all 16 patients with HBsAg seroclearance remain HBsAg negative,undetectable HBV-DNA,no patient experience reactivation of hepatitis B virus.However,of the 97 patients without HBsAg seroclearance,15(15.5%)patients experience reactivation of hepatitis B virus,with a median time of 15(4-23)months after transplantation,indicating HBsAg seroclearance induced by adoptive immunity transfer of immunity to hepatitis B virus effectively help to prevent reactivation of hepatitis B virus in recipients after transplantation.By multivariate Cox analysis,donor HBsAb+/HBcAb+(HR=6.75,95%CI=2.57-18.35,P<0.001)was a only major factor affecting HBsAg seroclearance in recipient after transplantation.2.Comparison of lamivudine versus entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients(1)Clinical data and grouping:234 HBsAg positive patients undergoing allogeneic stem cell transplantation received lamivudine or entecavir as anti-HBV prophylaxis were included in the second part of the study.119 patients in lamivudine group,including 71 male and 48 female with median age 27(18-58)years.Primary diseases include 41 cases of acute lymphoblastic leukemia,54 cases of acute myeloid leukemia,4 cases of aplastic anemia,12 cases of chronic myeloid leukemia,4 cases of myelodysplastic syndrome,4 cases of non Hodgkin’s lymphoma.The methods of transplantation include peripheral blood stem cell transplantation in 93 cases,3 cases of bone marrow transplantation,23 cases of peripheral blood stem cell combined with bone marrow transplantation.115 patients in entecavir group,including 70 male and 45 female with median age 28(14-62)years.Primary diseases include 42 cases of acute lymphoblastic leukemia,57 cases of acute myeloid leukemia,3 cases of aplastic anemia,9 cases of chronic myeloid leukemia,2 cases of myelodysplastic syndrome,2 cases of non Hodgkin’s lymphoma.The methods of transplantation include peripheral blood stem cell transplantation in 90 cases,2 cases of bone marrow transplantation,23 cases of peripheral blood stem cell combined with bone marrow transplantation.There was no statistical difference ofclinical databetween the two groups(P>0.05).(2)Viral response and hepatitis B surface antigen clearance:The median anti HBV treatment time to complete virological response was 2(1-4)months in the of entecavir group and 3(2-4)months in the lamivudine group for patients with baseline HBV-DNA more than 105copies/ml(P=0.018).Additionally,16 recipients(13.4%)in the lamivudine group and 14 recipients(12.2%)in the entecavir group exhibit HBsAg seroclearance with a median time of 2.5(1.5-3)months after transplantation,all these recepientsreceived grafts fromHBsAb+andHBcAb+donors.The incidence of HBsAg seroclearance and time of occurrence has no significant difference between two groups(P>0.05).All patients who achieved HBsAg seroclearance remained HBsAg-negative and HBV-DNA undetectable with a median follow-up time of 24(16-24)months,and none of them developed HBV reactivation.(3)Reactivation of hepatitis B virus:After a median follow-up time of 24 months after transplantation,28 patients(23.5%)in the lamivudine group and 2 patients(1.7%)in the entecavir group experienced HBV reactivation(P<0.001).The median times to HBV reactivation for the two groups were 17(3-23)months and 18(18-21)months.respectively.23 of 28(82.1%)in the lamivudine group and 1 of 2 cases in the entecavir group who experienced hepatitis B virus reactivation had baseline HBV DNA more than 105copies/ml.The cumulative incidence rates of HBV reactivation at months 6,12,and 24 following transplantation were 3.0%,7.0%,and 24.0%in the lamivudine group,and 0%,0%,and 2.0%in the entecavir group(P<0.001).All patients with HBV reactivation underwent testing for drug-resistance mutations.The incidence rates of drug-resistance mutations were 21.0%(25 of 119 patients)in the lamivudine group and 1.0%(1 of 115 patients)in the entecavir group(P<0.001).The incidence rates of primary drug-resistance mutations were 4.2%(5 of I 19 patients)in the lamivudine group and 0%(none of 115 patients)in the entecavir group.(4)Hepatitis due to hepatitis B virus reactivation:In the lamivudine group,18 of 28(64.3%)patients with HBV reactivation developed varying degrees of hepatitis,including 13 cases of mild or moderate hepatitis and 5 cases of severe hepatitis.The median times to onset of mild or moderate and severe hepatitis were 19(7-23)months and 5(3-9)months,respectively.In the entecavir group,however,only one patient with HBV reactivation developed a case of mild hepatitis,which occurred at 18.0 months post-transplantation.At months 6,12,and 24 post-transplantation,the cumulative incidence rates of any severity of HBV reactivation-related hepatitis were 3.0%,7.0%,and 15.0%in the lamivudine group,and 0%,0%,and 1.0%in the entecavir group(P<0.001).For severe hepatitis,cumulative incidence at the three time points mentioned were 3.0%,3.0%,and 4.0%in the lamivudine group,and 0%,0%,and 0%in the entecavir group(P<0.001).In the lamivudine group,4 of 5 patients with severe hepatitis died of multiple organ failure(MOF)secondary to hepatitis.Nevertheless,all 13 patients with mild/moderate hepatitis were cured after switching to 1 mg/day entecavir for anti-HBV therapy.In the entecavir group,the patient who developed hepatitis was cured after supportive treatment.(5)Risk factor analysis of HBV reactivation and subsequent hepatitis:In order to identify predisposing risk factors for HBV reactivation and subsequent hepatitis following allo-HSCT,we performed univariate and multivariate analyses using the Cox proportional hazard model.Multivariate analysis showed that patients treated with lamivudine had a considerably higher risk of HBV reactivation and subsequent hepatitis than those treated with entecavir(HR=16.91,95%CI=8.25-52.23,P<0.001 for HBV reactivation;HR=6.40,95%CI=3.25-14.12,P<0.001 for subsequent hepatitis).Multivariate analysis showed that baseline hepatitis B virus load of recepients(HR=4.30,95%CI=2.23-11.58,P<0.001)were significant risk factors for HBV reactivationAdverse reactions(ADRs)occurring with a frequency of>5%in both treated groups are fatigue,abdominal discomfort or pain,diarrhea,dizziness.There was no statistical difference in the proportion of patients experiencing these ADRs between the two groups.No grade 3-4 drug-related hematological or renal toxicities or abnormal laboratory findings occurred during treatment.Conclusion:1.Our study demonstrated the existence of immunity transfer of immunity to hepatitis B virus in allogeneic hematopoietic stem cell transplantation,which exhibited a complete reconstruction of adoptive immunotherapy different from that of solid organ transplantation.The immunity transfer of immunity to hepatitis B virus help to transfer hepatitis B virus specific immunity from donors to recipients,leading to seroconvert from HBsAb-to HBsAb+in pre-transplant HBsAb-recipients so as to significantly decreasedoccurrence of hepatitis B reactivation after transplantation.2.Immunity transfer of immunity to hepatitis B virus also help to reduce HBsAb loss in pre-transplant HBsAb+recipients,so as to significantly decreased the occurrence of infection or reactivation of hepatitis B virus after transplantation.3.Adoptive immunity transfer of immunity to hepatitis B virus resulted in seroclearance of hepatitis B surface antigen in hepatitis B infection patients and acted synergistically with nucleoside drugs,resulting in sustained seroclearance of hepatitis B surface antigen,persisted hepatitis B virus DNA negative and normal liver function in patients with pre-transplant hepatitis B infection,suggesting complete cure of hepatitis B virus infection in the patients.4.Entecavir can significantly reduce the incidence rate of HBV reactivation and associated severe hepatitis as compared with lamivudine,entecavir also has more potent anti-viral efficacy and lower incidence of drug resistance.The two drugsacted synergistically withadoptive immunity transfer of immunity to hepatitis B,resulting in sustained seroclearance of hepatitis B surface antigen.However,the two drugs show similar potency in the seroclearance of hepatitis B surface antigen,adoptive immunity transfer of immunity to hepatitis B virus might play a more important role.5.Our study suggest that the use of adoptive immunity transfer of immunity to hepatitis B virus combined with nucleoside drugs for prevention and treatment of hepatitis B virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation might be a promising method. |
PDF Full Text Request